Start with three questions: what was tested, who or what was studied, and what changed? This approach helps you tell a promising mechanism from an outcome measured in people.
A useful research summary states what was studied, what was measured and what remains unanswered. A mechanism, an animal result and a controlled human trial are different kinds of evidence.
Peptide evidence explorer: compare the actual study
“Human research” can mean very different things. A paper may measure a peptide already present in the body, give a defined material to participants, or use cells originally taken from human tissue. Only the second is an intervention administering that peptide to people.
These selected records show how to keep the material, model and question together. They complement the individual Research Snapshots with paper-level examples. They are not study counts, an exhaustive literature search or a ranking of compounds.
| Material and source date | What was studied | What this record does not establish | Read the source |
|---|---|---|---|
| BPC-157 2011; online 2010 | Preclinical: rat tendon explants and cultured tendon cells. The paper examines cell movement, outgrowth and survival under stress. | This is not a human tendon-healing trial. A cell-movement result cannot supply a human recovery time. | Chang et al., PMID 21030672 Compound research context |
| KPV 2008; online 2007 | Preclinical: human-derived intestinal and immune cell lines, plus two mouse colitis models; PepT1 uptake and inflammatory signalling were examined. | Human-derived cells are laboratory models. This record does not establish benefit in people with bowel disease. | Dalmasso et al., PMID 18061177 Compound research context |
| MOTS-c 2015 | Preclinical: cellular metabolism and mouse experiments, including folate/purine pathways and AMPK-linked responses. | Findings from these models do not establish the effects of administering a research preparation to people. | Lee et al., PMID 25738459 Compound research context |
| Naturally occurring MOTS-c in the human arm 2021 | Human measurements around exercise; the same paper also contains separate mouse experiments with administered MOTS-c. | The human arm measured the body’s own peptide. It was not a human trial administering MOTS-c. Keep the human and mouse arms separate. | Reynolds et al., PMID 33473109 Compound research context |
| Tesamorelin 2007 | Human intervention: a randomized, placebo-controlled trial in 412 adults living with HIV and excess abdominal fat. The primary endpoint was CT-measured visceral fat change over 26 weeks. | Retain the population, endpoint and trial formulation. This does not establish a result for every adult or authenticate a catalogue vial. | Falutz et al., PMID 18057338 Compound research context |
| Long-acting CJC-1295 2006; online 2005 | Human intervention: randomized, placebo-controlled studies in healthy adults examining GH, IGF-I and pharmacokinetics. | The long-acting material is not interchangeable with a No DAC label. Hormone measurements also are not every proposed functional outcome. | Teichman et al., PMID 16352683 Compound research context |
| GHK-copper complex 1988 | Laboratory: fibroblast cultures and collagen synthesis measurements. | A culture result does not establish a cosmetic or clinical outcome from a different formulation in people. | Maquart et al., PMID 3169264 Compound research context |
Read missing information accurately
- Not yet reviewed: no source assessment has been completed for that question.
- No evidence identified in reviewed sources: the checked records did not answer it. This is not proof that no study exists anywhere.
- Preclinical evidence: findings from laboratory or animal models.
- Human evidence: state whether it is an observation or an intervention, and name the population.
- Established clinical benefit: requires a separate, indication-specific assessment. The presence of a paper or trial registration does not establish it.
Source records checked 10 November 2026. The summaries use the cited abstracts and publication records; they do not imply a full-text systematic review or an independent scientific review. Publication years describe the papers, not a claim that they are the newest research.
Download the blank study-evidence worksheet (CSV). Record the exact material, comparator, endpoint, uncertainty and source before writing your conclusion. For the separate sample-testing question, use the analytical-question worksheet.
Write down the question before the conclusion
Start with the study’s purpose in one sentence. What uncertainty were the investigators trying to reduce? A paper can be valuable without answering the broad question that brought you to it. The task is to identify its actual contribution rather than force it into a pre-existing expectation.
Read the title and abstract as a map, then inspect the methods and results. If a promotional summary makes a sweeping claim, find the corresponding endpoint in the original paper. Sometimes the measured outcome is narrower, or the language online omits an important model limitation.
Keep your own question alongside the authors’ question. They may overlap only partly. Noticing that gap is a useful result of reading, not a failure to find a positive answer.
Identify the model and population
Record whether the work involves cells, isolated tissue, an animal model or people. If it involves people, record the relevant population and study design. An outcome can be real within one setting without being established in another.
The BPC-157 tendon-cell paper is a useful example of a clearly bounded experimental setting. The Retatrutide phase 2 trial is a different type of investigation with a defined clinical context. Putting both under the word “research” does not make their claims equivalent.
This distinction should remain visible when you summarise the work for someone else. “Observed in the named laboratory model” communicates more useful information than removing the model and retaining only a benefit-sounding phrase.
The BPC-157 research profile and Retatrutide research profile provide separate reading paths.
Check which material was actually used
Read the compound identity, formulation and preparation details relevant to the study. A fragment, full-length molecule and modified analogue may appear together in discussions without being interchangeable materials.
This is especially important when a commercial research name is used loosely. Before borrowing an outcome or mechanism, confirm that the paper’s material matches the identity under discussion. A name alone cannot resolve sequence, terminal modification or formulation questions.
The study material and the supplied catalogue stock also need separate records. Even a strong publication is not an independent test of a vial currently offered on a website. Research evidence and batch evidence serve complementary purposes.
Find the primary endpoint and comparator
The endpoint tells you what changed, or what the investigators intended to measure. The comparator provides the context for interpreting that change. A hormonal response, cell migration, a mechanical measurement and a clinical outcome answer different questions.
Look for the distinction between a primary endpoint and exploratory findings. A paper may contain many measurements; an appealing secondary result should not be presented as though it was the central question without acknowledging that context.
Record the direction and practical meaning of the finding in the authors’ terms. Avoid converting a biomarker into a different outcome merely because the proposed mechanism sounds plausible.
| What you read | Useful follow-up |
|---|---|
| A pathway changed | Was a functional outcome measured? |
| A result was statistically significant | How large and precise was the finding? |
| A comparison favoured the intervention | What was the comparator and study setting? |
| A subgroup appeared different | Was the analysis planned and how limited is it? |
Read uncertainty as part of the result
Study size, duration, model choice and measurement methods all shape what can be concluded. A limitation is not an automatic reason to dismiss a paper; it helps define where the finding is useful and where more evidence is needed.
Check whether the authors distinguish observed data from their explanation of it. An attractive mechanism can guide further research without being the only possible interpretation. Likewise, a result from one experiment does not establish independent replication.
When human outcomes are discussed, adverse events and discontinuations belong in the same reading process as favourable endpoints. A balanced summary does not turn a study into a promise for an individual reader.
Follow the references without losing the thread
A review can organise a field, but open the original study for a specific finding you intend to rely on. Check the date, material and model rather than assuming every reference supports the sentence in exactly the same way.
Be cautious when a chain of websites cites one another instead of the original paper. Trace the claim back to the experiment or official document. If the original does not answer the question, preserve that uncertainty in your notes rather than strengthening the claim through repetition.
Use the source trail to refine your question. You may discover that the evidence concerns a different formulation, endpoint or population. That is useful context for deciding which paper to read next.
A one-page research note
- Citation and publication date.
- Your question and the authors’ question.
- Model or study population.
- Exact material and formulation.
- Comparator and primary endpoint.
- Main finding in its original context.
- Important limitations and unanswered questions.
- Whether independent work supports the same conclusion.
Connect the paper to the right website page
Use a research profile or guide for the literature question. Use the Repair & Recovery catalogue for listed material options. Use Lab Results for sample-specific analytical documentation. Each route has a different purpose.
A well-connected site helps you move between them while preserving those distinctions. If you are comparing products, start with identity and specifications. If you are comparing evidence, start with study design and endpoints. Do not let the presence of a purchase button decide how strongly a scientific claim is phrased.
Frequently asked questions
Is an animal study worthless for human questions?
It can be informative for its model and research purpose. It does not, by itself, establish a human outcome.
Does a mechanism prove a benefit?
A mechanism can explain a hypothesis or observation. The outcome still needs appropriate evidence in the relevant setting.
Can a published paper replace a COA?
No. A paper describes its study material; a COA concerns specified tests on a submitted sample.
Sources and further reading
Technical sources support the analytical concepts; scientific findings belong to their stated study models. Examples and review worksheets in this guide are educational tools, not Peptide Place batch results.
Editorial and corrections policy · Report a factual or documentation issue
Put the explanation into practice
Choose one compound and check its name, current sizes and research summary. Then compare a related compound before opening a source report. BPC-157 and TB-500 provide a useful recovery comparison; GHK-Cu introduces the skin and collagen conversation. For different metabolic pathways, compare Retatrutide and MOTS-c.
Open the comparison tool or return to the beginner learning path.
Compare two peptide studies without mixing their conclusions
Put the studies side by side before comparing their headline results. Write one line for the exact material, model or population, comparator, endpoint and follow-up in each. If one paper measures cell migration and another measures a clinical outcome, you have two different questions rather than a direct contest between peptides.
A direct comparison studies the alternatives within the same design. Comparing separate trials is harder: participant selection, background treatment, duration and outcome definitions may differ. A larger-looking number in one trial does not by itself show that its intervention is superior. Keep these differences visible in your notes.
Randomization, masking and missing participants
Randomization uses a chance-based allocation process to help create comparable groups. Masking, also called blinding, keeps specified people unaware of allocation where feasible. Neither removes every possible source of bias. Check who knew the assignments, how outcomes were assessed and which participants were included in the final analysis.
People who leave a trial can affect the interpretation. Read how missing outcomes were handled and whether the main result depends on assumptions about them. The CONSORT 2025 reporting guidance helps readers locate trial registration, protocols, participant flow, outcomes and harms. Complete reporting makes assessment easier; it does not guarantee a flawless study.
Peptide clinical trials explained
A human clinical trial tests a defined intervention in people under a research protocol. It is different from observing a molecule already present in the body, studying cells or administering a compound to animals. The word “human” alone does not tell you whether an intervention was tested.
What do the phases mean?
Health Canada explains four common clinical-trial phases. Broadly, phase 1 examines early safety and exposure; phase 2 studies activity and safety in a larger relevant group; phase 3 makes larger-scale evaluations and comparisons; phase 4 follows an authorized drug after marketing. Designs can combine phases. Phase numbers describe development questions, not a promise that a trial succeeded.
Ask what this particular trial measured, rather than inferring a finding from its phase. A trial can be registered or authorized before it has results. “Recruiting,” “completed” and “results published” are different states. A completed trial record may still lack a full report, and an abstract may omit details available in the paper or protocol.
Registration, results and market authorization
For a Canadian regulatory question, read Health Canada’s guidance on peptide research and clinical trials. Trial authorization and authorization to market a medicine are different decisions. Findings concern the studied product, formulation and population; they do not establish that an unrelated research vial is equivalent.
Three useful questions before sharing a finding
- Was this an intervention trial, an observation or preclinical work?
- What was the prespecified main outcome, and what harms or withdrawals were reported?
- Does the source support the exact material, population and claim in the summary?
The Retatrutide research profile provides a clinical-research reading path. The BPC-157 tendon research guide illustrates a different experimental setting. For a natural-peptide observation versus administration, compare the distinctions in the MOTS-c profile. These links are examples for reading evidence, not a declaration that every compound has reached every trial stage.
Does statistical significance prove an important benefit?
No. Read the size of the difference, its uncertainty and the endpoint’s practical meaning. A statistically detectable change in a marker may leave a clinical question unanswered. A result that is not statistically significant also needs context: it may reflect limited precision rather than demonstrating that two options are equivalent.
Use the glossary for evidence terms and the comparison directory to find compound-specific discussions. A certificate of analysis answers a material-testing question, not whether a clinical claim is established.
How to find published peptide studies
Start with a precise question and the exact material. “Does this peptide work?” is too broad to guide a useful search. “What did this BPC-157 tendon experiment measure?” gives you a compound, a tissue and an endpoint to investigate.
- Collect the names. Record the compound’s accepted name and any documented research code. Tirzepatide appears in early work as LY3298176; retatrutide as LY3437943. A seller’s blend name may not be a term used in the scientific literature.
- Search one concept first. Enter the compound in PubMed. Add a tissue or study question if the results are too broad. Try a documented synonym separately if results are sparse.
- Read the record. Confirm the title, publication date, article type and abstract. Check notices of corrections, retractions or expressions of concern where shown.
- Open the original paper. Follow the publisher or free-full-text link. An abstract can help locate relevant work while leaving important methods and limitations out.
- Keep a search note. Save the terms, date, paper identifier and reason for including or excluding it. A later search can produce different results.
A search you can adapt
Try (tirzepatide OR LY3298176) AND receptor to connect a familiar name with its development code. PubMed uses OR to include alternatives and AND to combine concepts. Inspect the search translation and results before assuming the database interpreted a name as intended.
A narrow “clinical trial” filter can miss earlier laboratory work and records not fully indexed. A broad search can include reviews, commentary and studies that mention the peptide without testing it. Use filters deliberately, then read the study itself. The official PubMed User Guide explains search translation, filters and identifiers.
Keep papers and trial registrations separate
A registration describes a planned or ongoing study and may later include results. A published paper reports a particular analysis. Match the trial identifier, intervention and population across the two. Do not turn a recruiting status, a sponsor headline or a completed date into a published result.
For chemical-name checks, use the identity guide. For the evidence you found, return to the clinical-trial reading questions. BPC-157, MOTS-c and retatrutide provide different examples of how to follow a source trail.

